A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination With Palliative Radiotherapy in Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2017
At a glance
- Drugs M 3541 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors EMD Serono Research & Development Institute
- 04 Oct 2017 Planned initiation date changed from 14 Sep 2017 to 2 Oct 2017.
- 09 Sep 2017 Status changed from not yet recruiting to recruiting.
- 27 Jul 2017 New trial record